🧪 AMPLIFY-NEOVAC Trial

The AMPLIFY-NEOVAC Trial is a Phase I multicenter clinical trial investigating the combination of an IDH1 R132H-targeted peptide vaccine with an anti–PD-L1 immune checkpoint inhibitor in patients with newly diagnosed IDH1-mutant astrocytomas.

To evaluate the safety, tolerability, and immunogenicity of a combination immunotherapy:

1. IDH1 R132H peptide vaccine (used in the NOA-16 trial)
2. Atezolizumab (a PD-L1 immune checkpoint inhibitor)

• Adults with newly diagnosed WHO grade III or IV IDH1 R132H-mutant astrocytomas
• Must have completed standard-of-care therapy (surgery and radiotherapy)
• Patients with or without prior temozolomide exposure may be included

• NOA-16 showed the IDH1 R132H vaccine is safe and immunogenic
• Adding a PD-L1 inhibitor may enhance T cell infiltration and sustain immune responses by preventing T cell exhaustion
• The goal is to amplify anti-tumor immunity and improve long-term outcomes

• Open-label, Phase I
• Two arms:
  1. IDH1 vaccine alone
  2. IDH1 vaccine + atezolizumab
• Evaluates:
  1. Adverse events
  2. Vaccine-specific T cell responses
  3. Tumor progression-free survival (PFS)

• Atezolizumab is already approved for several cancers (lung, bladder) and blocks PD-L1 → PD-1 signaling
• The vaccine uses the same 20-mer peptide from NOA-16, targeting the IDH1 R132H mutation
• The trial will help determine if combining checkpoint blockade with vaccination improves response durability

1. Immune-related adverse events due to checkpoint inhibition
2. Blood-brain barrier may limit immune cell access
3. Small patient population (IDH1-mutant astrocytomas are rare)

• NOA-16 demonstrated feasibility and immune activation using the IDH1 vaccine alone
• AMPLIFY-NEOVAC builds on this by aiming to strengthen and prolong the anti-tumor immune response

The AMPLIFY-NEOVAC Trial is an important next step in personalized glioma immunotherapy, exploring whether checkpoint blockade can synergize with neoantigen vaccination to generate deeper, longer-lasting anti-tumor responses in patients with IDH1 R132H-mutant gliomas.

• NOA-16 Trial
• IDH1 Mutation
• Personalized mRNA Neoantigen Vaccine
• Checkpoint Inhibitor
• Cancer Vaccine for Glioma

If you're studying feasibility and safety of personalized vaccines → NOA-16 is essential.

If you're interested in advanced therapeutic strategies and combination immunotherapy → AMPLIFY-NEOVAC is more cutting-edge. ¹⁾